- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that its corporate information is now available via Standard & Poor's ("S&P") Market Access Program. The Company's corporate description was published in the Daily News Section of S&P's Standard Corporation Records on July 31, 2007.
Standard Corporation Records is a recognized securities manual for the "Blue Sky" Standard Manual Exemption for secondary trading in 38 states. As part of S&P's Market Access Program, the Company's corporate information will be made available through S&P's Advisor Insight website ( http://www.advisorinsight.com ). The website provides financial advisors with share price, volume dividends, shares outstanding, company financial position and earnings on thousands of companies.
"Being listed in Standard & Poor's is yet another step in our plan to increase our exposure to the investing community," stated Eugene Seymour, MD, NanoViricide's CEO. "We are very pleased with Standard & Poor's decision to include us in its Corporation Records and initiate coverage of us in its Market Access Program."
About NanoViricides, Inc.
NanoViricides, Inc. ( http:// www.nanoviricides.com ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, rabies, dengue fever, HIV, hepatitis C, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors.
Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward looking statements are subject to known and unknown risks, uncertainties and other factors including the availability of adequate financing, the success of the Company's research and development strategy, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Such risks, uncertainties and other factors may cause actual results, performance, or achievements of the Company to be different from those expressed or implied by the Company.
For more information, please click here
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Arrowhead to Present at Upcoming March Conferences March 1st, 2016
Nanoparticles present sustainable way to grow food crops May 1st, 2016
Cooling graphene-based film close to pilot-scale production April 30th, 2016
Personal cooling units on the horizon April 29th, 2016